IMPROVEMENT OF WATER SOLUBILITY AND DISSOLUTION OF ATORVASTATIN
Abstract
The aim of this study was to increase the solubility and dissolution of atorvastatin by complexing it with b-cyclodextrin. The solubility of atorvastatin increased with both increasing pH and b-CD-concentration. Solid complexes prepared by physical mixing, kneading, co-precipitation and freeze-drying methods were characterized using Fourier transform infrared spectroscopy (FTIR). In vitro studies showed that the solubility and dissolution rate of Atorvastatin were significantly improved by Complexation with B-cyclodextrin with respect to the drug alone. In contrast, freeze-dried complexes showed higher dissolution rate than the other complexes. Tablets of atorvastatin were prepared and it showed a high solubility.
Keywords: Inclusion complex; atorvastatin; cyclodextrin; Solubility; Dissolution properties
References
Lennernas H: Clinical pharmacokinetics of atorvastatin. Clin.Pharmacokinet 2003; 42: 1141–1160.
Kim JS, kim MS, Park HJ, Jin SJ, Lee S and Hwang SJ: Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. International Journal of Pharmaceutics 2008; 359: 211-219.
Janet Kerc of Novartis obtained an US patent (US 2004/0138290), which describes a stable formulation of Atorvatstatin Calcium for oral administration.
Nancy Mills of Warner-Lambert Company obtained a US patent (US 5,686,104), which claims a stable atorvastatin formulation containing one of the drug-stabilizing agent depending on the method of preparation.
Higuchi T, Connors KA: Phase-solubility techniques. Adv Anal Chem Instrum. 1965; 4: 117–212.
Martin M, Del, Valle: Cyclodextrins and their uses. A review, Process Biochemistry. 2004: 39; 1033–1046.
Kearny, Albert S, Crawford LF: The interconversion kinetics, equilibrium and solubilities of the lactone and hydroxy acid forms of the HMG-CoA Reductase Inhibitors. Pharm Research. 1993; 10: 1461-1465.
Zingone G, Rubessa F: Preformulation study of the inclusion complex warfarin- β-cyclodextrin, Int. J. Pharm 2005: 291: 3–10.
Shimpi S, Chauhan B: Cyclodextrins: Application in different routes of drug administration. Acta Pharm 2005; 55: 139–156.
Xianhong W, Fei T, Zhijun J, Ziuyang L: Preparation and study the 1:2 inclusion complex of carvedilol with β-cyclodextrin. Journal of Pharmaceutical and Biomedical Analysis 2004; 34: 517–523.
Loftsson T, Brewster ME: Pharmaceutical applications of cyclodextrins: A. Drug solubilisation and stabilization. Journal of Pharmaceutical Sciences. 1996; 85: 1017–1025.
Mukne AP, Nagarsenker MS: Triamterene β-cyclodextrin systems. Preparation,characterization and in vivo evaluation. AAPS PharmSciTech. 2004; 5 : 1-9.
Ann MS, Nguyen BN: Effect of hydroxypropyl-β-cyclodextrin-complexation and pH on solubility of camptothecin. Int. J. Pharm. 2004; 284: 61–68.
Baboota S, Agrawal SP: Formulation of Meloxicam cyclodextrin complexes incorporated tablets. The Indian Pharmacist. 2005; 62-66.
Nalluri BN, Chowdhary KPR: Physicochemical characterization and dissolution properties of nimesulide cyclodextrin binary systems. AAPS PharmSciTech. 2003; 4: 1-12.
Ghorab MM, Mekhel MM: Tablet formulation containing meloxicam and β-cyclodextrin: mechanical characterization and bioavailability evaluation. AAPS PharmSciTech. 2004; 5: 1-
